Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6212 followers
Created: 2025-07-26 06:11:06 UTC

Alembic Pharma Secures USFDA Approval for Carbamazepine Tablets 💊 | Market Potential: $71M | MCap XXXXXXXX Cr

- USFDA grants final approval for Carbamazepine Extended-Release Tablets (100mg, 200mg, 400mg).
- Therapeutically equivalent to Novartis' Tegretol-XR.
- Used for anticonvulsant therapy and trigeminal neuralgia pain.
- Estimated market size: $71M (12 months ending March 2025, per IQVIA).
- Cumulative USFDA approvals: XXX (202 final + XX tentative).
- Vertically integrated R&D pharma company with strong branded generics presence in India.
- Operates with 5,500+ field force personnel and USFDA-approved manufacturing facilities.

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

![](https://pbs.twimg.com/media/GwwzfM_WIAApi9K.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948989433195139199/c:line.svg)

**Related Topics**
[mcap](/topic/mcap)
[$71m](/topic/$71m)
[investment](/topic/investment)
[novartis](/topic/novartis)
[$novnsw](/topic/$novnsw)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/_Investor_Feed_/status/1948989433195139199)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Investor_Feed Avatar Investor Feed @Investor_Feed on x 6212 followers Created: 2025-07-26 06:11:06 UTC

Alembic Pharma Secures USFDA Approval for Carbamazepine Tablets 💊 | Market Potential: $71M | MCap XXXXXXXX Cr

  • USFDA grants final approval for Carbamazepine Extended-Release Tablets (100mg, 200mg, 400mg).
  • Therapeutically equivalent to Novartis' Tegretol-XR.
  • Used for anticonvulsant therapy and trigeminal neuralgia pain.
  • Estimated market size: $71M (12 months ending March 2025, per IQVIA).
  • Cumulative USFDA approvals: XXX (202 final + XX tentative).
  • Vertically integrated R&D pharma company with strong branded generics presence in India.
  • Operates with 5,500+ field force personnel and USFDA-approved manufacturing facilities.

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

XXX engagements

Engagements Line Chart

Related Topics mcap $71m investment novartis $novnsw stocks healthcare

Post Link

post/tweet::1948989433195139199
/post/tweet::1948989433195139199